Bluesky Facebook Reddit Email

A new strategy for treating atrial fibrillation: Targeting the TRPC3 channel

11.20.25 | Toho University

SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.


A research group led by Assistant Professor Megumi Aimoto and Professor Akira Takahara at the Faculty of Pharmaceutical Sciences, Toho University, revealed that pyrazole-3 (Pyr3), a selective inhibitor of the transient receptor potential canonical-3 (TRPC3) channel, a calcium-permeable channel in the heart, prevents the persistence of atrial fibrillation. Atrial fibrillation is a tachyarrhythmia that occurs in the atria and is a major cause of stroke and heart failure. This study demonstrated that the TRPC3 channel is a promising new therapeutic target for atrial fibrillation. Drug therapy targeting TRPC3 channels is expected to provide a new approach for “overcoming” cardiovascular diseases associated with aging and lifestyle habits, including atrial fibrillation. These findings were published in the Biological and Pharmaceutical Bulletin on October 15, 2025.

A research group led by Assistant Professor Megumi Aimoto and Professor Akira Takahara at the Faculty of Pharmaceutical Sciences, Toho University, revealed that pyrazole-3 (Pyr3), a selective inhibitor of the transient receptor potential canonical-3 (TRPC3) channel, a calcium-permeable channel in the heart, prevents the persistence of atrial fibrillation.

Atrial fibrillation is a tachyarrhythmia that occurs in the atria and is a major cause of stroke and heart failure. This study demonstrated that the TRPC3 channel is a promising new therapeutic target for atrial fibrillation. Drug therapy targeting TRPC3 channels is expected to provide a new approach for “overcoming” cardiovascular diseases associated with aging and lifestyle habits, including atrial fibrillation.
These findings were published in the Biological and Pharmaceutical Bulletin on October 15, 2025.

Key Points

Journal:
Biological and Pharmaceutical Bulletin (October 15, 2025) Vol. 48, No. 10, pp. 1547–1554

Article Title:
Anti-atrial Fibrillatory Effects of the TRPC3 Channel Inhibitor Pyrazole-3 in Rats with Atrial Enlargement Induced by Chronic Volume Overload

Authors:
Megumi Aimoto, Yoshinobu Nagasawa, Taichi Kusakabe, Keisuke Kato, Akira Takahara

DOI:
10.1248/bpb.b25-00415

Biological and Pharmaceutical Bulletin

10.1248/bpb.b25-00415

Experimental study

Animals

Anti-atrial Fibrillatory Effects of the TRPC3 Channel Inhibitor Pyrazole-3 in Rats with Atrial Enlargement Induced by Chronic Volume Overload

15-Oct-2025

The authors declare no conflict of interest.

Keywords

Article Information

Contact Information

Akira Muto
Toho University
akira.muto@med.toho-u.ac.jp

Source

How to Cite This Article

APA:
Toho University. (2025, November 20). A new strategy for treating atrial fibrillation: Targeting the TRPC3 channel. Brightsurf News. https://www.brightsurf.com/news/12DR9MO1/a-new-strategy-for-treating-atrial-fibrillation-targeting-the-trpc3-channel.html
MLA:
"A new strategy for treating atrial fibrillation: Targeting the TRPC3 channel." Brightsurf News, Nov. 20 2025, https://www.brightsurf.com/news/12DR9MO1/a-new-strategy-for-treating-atrial-fibrillation-targeting-the-trpc3-channel.html.